Doctor Profile

Doctor Profile
Dent Rebecca Alexandra
Dr Dent Rebecca Alexandra
National Cancer Centre Singapore
Division of Medical Oncology
Senior Consultant
MSc (Canada), MD (Canada), FRCP (Canada)
Education

2005-2007         University of Toronto - Toronto, Canada

                        Master of Science, Clinical Epidemiology & Biostatistics,

 

1996-2000         McMaster University, Faculty of Medicine - Hamilton, Canada

                        Doctor of Medicine

 

1991-1995         Queen’s University, Faculty of Arts & Science - Kingston, Canada

Bachelor of Science- 1st Class Honors

Professional Appointments and Committee Memberships

2011 – present   Senior Consultant, Department of Medical Oncology Singapore

   Breast Team, National Cancer Centre Singapore

 

2011 – present   Associate Professor, Duke-NUS Singapore

                            Mentor for Duke-NUS 3rd year medical school student theses (group of 6)

                            Clinical Expert for Khoo Scholars Program (research mentorship program for junior consultants)

Other Appointments

2012-present     Head, Breast Cancer Research, SingHealth/Duke-NUS, Singapore                                       Singapore

 

2012-present     Head, Breast Medical Oncology Team, National Cancer Centre Singapore                            Singapore

 

2012-present     Co-Chair, Founder, Annual Asia-Pacific Breast Cancer Symposium                                      Singapore

 

2011-present     Co-Chair, Triple Negative Breast Cancer Symposium        

2011-present     Journal of Clinical Oncology Editorial Board

2014-present     Translational Steering Committee for the OlympiA Trial (Olaparib as Adjuvant Treatment in Patients with Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer)

 

2012-present     International Steering Committee for the ETNA Study, Michelangelo Foundation

 

2007-present     International Steering Committee for BEATRICE

Academic/Industry led intl. trial of Bevacizumab for Adjuvant Treatment of Triple Negative Breast Cancer

 

2007-present     Member, Translational Committee for the BEATRICE trial

Awards

2011                 ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research - Flims, Switzerland

Supervised Dr. Vikaash Kumar

 

2009                 Merit Award, ASCO Breast Meeting - San Francisco, USA

Supervised Dr. Saira Nasim

2008                 Outstanding Teaching Award, Medical Oncology Teaching Program - Toronto, Canada

2005                 Helen Marion Walker Women’s Health Research Award - Toronto, Canada

2002                 Best House staff Award, Department of Internal Medicine, Mount Sinai Hospital - Toronto, Canada

2001                 First Prize, Division of Oncology Annual Research Day, University of Toronto - Toronto, Canada

Publications and Research Trials

 

1.     Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HJ, Sawka CA, Lickley LA, Ping S, Narod SA. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 2007 Aug 1;13 (15 Pt 1):4429-34.

 

2.     Dent R, Warner E. Screening for Hereditary Breast Cancer. Seminars in Oncology. 2007 Oct;34(5):392-400.

 

3.     Dent R, Hanna W, Trudeau M, Rawlinson E, Sun P, Narod SA. Patterns of Metastatic Spread in Triple-Negative Breast Cancer. Breast Cancer Res Treat. 2009 May; 115 (2):  423-8. 

 

4.     Dent R, Hanna W, Trudeau M, Rawlinson E, Sun P, Narod S. Time to Recurrence in Basal-type Breast Cancers: Effects of Tumor Size and Lymph Node Status. Cancer. 2009 Nov 1;115(21):4917-23.

 

5.     Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Sioleck M, Dent R, Lubinski J. Pathological Complete Response Rates in Young Women with BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. J Clin Oncol. 2010 Jan;20;28(3):375-9. 

 

6.     Dent R and Bristow RG. In Situ DNA Repair Assays As Guides to Personalized Breast Cancer Chemotherapeutics: Ready for Prime Time? J Clin Oncol, 2011, Apr 25.

 

7.     Verma S, Provencher L and Dent R. Emerging Trends in the Treatment of Triple-Negative Breast Cancer in Canada: a survey. Curr Oncol 2011 August 18 (4), 180-190.

 

8.     Lopes G and Dent R. Weighed, Measured, and Still Searching: Bevacizumab in the Treatment of Unselected Patients with Advanced Breast Cancer. The Oncologist, 2011; 16 (12): 1669-71.

 

9.     Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent R et al. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother. 2012 Dec; 46 (12): 1645-55. Epub 2012 Dec 18.

 

10.  Dent R, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2013 Sep 25;15(5):R88.

 

11.  Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013 Sep;14(10):933-42.

 

12.  Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Madhukumar P, Ooi WS, Chay WY, Dent R et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014 Jul;67(7):811-20. doi: 10.1016/j.jclinepi.2013.12.011. Epub 2014 Mar 18.  

 

13.  Dent R, Valentini A, Hanna W, Rawlinson E, Rakovitch E, Sun P, Narod SA. Factors associated with breast cancer mortality after local recurrence. Curr Oncol. 2014 Jun;21(3).

 

14.  Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Buchholz T, Gonzalez-Angulo AM. Survival of women with inflammatory breast cancer: a large population-based study. Ann Oncol. 2014 Jun;25 (6):1143-51.

 

15.  Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SK, Dent R, Song X, Robidoux A, Parpia S, Warr D, Rayson D, Pritchard KI, Levine MN. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat. 2014 Jul;146 (1):153-62. doi: 10.1007/s10549-014-3015-6. Epub 2014 Jun 13. PMID:24924416

 

16.  Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 2014 Aug;146 (3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8.

 

MEDIA PUBLICATIONS

 

2007 Dent R. Triple Negative Breast Cancer Canada

Live Broadcast CTV News: http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20070801/triple_negative_070801/20070801

2010 Dent R. Use of optical spectroscopy to monitor treatment response in locally advanced breast cancer Canada

Live Broadcast CTV am NEWS:

http://watch.ctv.ca/news/top-picks/custom-chemo/#clip303732

2011 Dent R. Treatment of triple negative breast cancer and the Triple Negative Breast Cancer Conference 2011 http://breakthrough.org.uk/our_work/our_research/triple_negative_breast_cancer_conference/


Fix an appointment with this doctor.
Book appointment online
64368088